Venus Remedies gets additional US patent nod for Vancoplus

Drug firm Venus Remedies today received additional patent approval from United States Patent and Trademark Office (USPTO) for its product 'Vancoplus', used for treating bacterial infections.

"Venus Remedies already has product patent for Vancoplus from USPTO. This additional patent with broader coverage for use and method of treatment will be beneficial for the company," Venus Remedies said in a filing to BSE.

The patent is valid till 2032 and the company has already initiated pre-Investigational New Drug meeting with US health regulator, it added.

Vancoplus is a highly effective remedy to control Methicillin-resistant Staphylococcus aureus (MRSA), VRSA (Vancomycin Resistance Staphylococcus aureus) and other bacterial infections.

Global anti-bacterial market is slated to reach around USD 64 billion by 2018, Venus Remedies said.

Shares of Venus Remedies were trading at Rs 302.80 per scrip in the afternoon trade on BSE, up 0.26 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Copy the characters (respecting upper/lower case) from the image.

EDITORIAL OF THE DAY

  • RBI lowers repo rates despite red flags concerning the economy

    The Reserve Bank of India (RBI) has gambled big time in lowering repo rates by 25 points for the third time in six months.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Nigavekar

Wanted: a central higher education scheme

During the one year that he has been at the ...

Rajgopal Nidamboor

The dappled fusion of our existence

Each of us, without exception, goes through a multitude of ...

Gautam Gupta

It’s ethnic wear all the way in Indian fashion

India is one of the most diverse countries in the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture